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Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease and also increases the incidence of
cerebrovascular disease. Prevention and management of cerebrovascular disease in patients with CKD, especially end-
stage kidney disease (ESKD), are different from those without CKD because of their specific pathophysiology. In patients
with ESKD on hemodialysis, a decrease in brain blood flow due to a decline in blood pressure during hemodialysis
might cause incident cerebrovascular disease. Cerebral microbleeds detected by magnetic resonance imaging, which are
much more prevalent in patients with CKD compared with the general population, might also cause incident brain
hemorrhage. For management for the hyperacute phase of brain infarction, thrombolytic therapy using recombinant
tissue plasminogen activator has been recently indicated for those patients. However, this indication should be carefully
evaluated because the risk of adverse events is higher in patients with CKD, especially ESKD. More recently, mechanical
thrombectomy has also been applied clinically. However, the efficacy of this treatment remains unknown in CKD and
ESKD patients. With regard to prevention, carotid endarterectomy and carotid artery stenting are performed for severe
carotid artery stenosis. Similarly to the treatment described above, the indication for these procedures should
be carefully evaluated because the incidence of stroke, myocardial infarction, and mortality is considered to
be high in patients with CKD. Administration of warfarin to hemodialysis patients with atrial fibrillation is
controversial because whether atrial fibrillation is involved in incident brain infarction and whether warfarin
prevents cerebrovascular disease remain unknown in those patients. Novel oral anticoagulants are now
available but are prohibited in severe CKD patients. Further investigation and accumulation of evidence are
required for prevention and management of cerebrovascular disease in patients with CKD, especially ESKD.
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The prevalence and mortality of cerebrovascular disease
are much higher in patients with chronic kidney disease
(CKD), especially those with end-stage kidney disease
(ESKD) compared with those without CKD. Therefore,
prevention and appropriate management of cerebrovas-
cular disease are crucial in this patient population [1, 2].
However, there are many differences in the methods of
prevention and management of cerebrovascular disease
between patients with and without CKD, especially those
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Characteristics of cerebrovascular disease in patients with
CKD
Effect of CKD on incident cerebrovascular disease
The prevalence of CKD in patients with cerebrovascular
disease is 20–35 % and 20–46 % in patients with brain
infarction and brain hemorrhage, respectively. Recent
prospective studies have demonstrated that renal dys-
function and proteinuria are independent risk factors for
incident cerebrovascular disease [2]. In contrast to a de-
crease in brain hemorrhage, the proportion of brainis article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Percentage of change in mean blood flow velocity of the middle
cerebral artery during tilt before and after hemodialysis. There are no
significant differences in percentage of change in mean blood flow
velocity of the middle cerebral artery (gray bars) between DM and non-
DM patients before hemodialysis, whereas percent reduction of mean
blood flow velocity of the middle cerebral artery after hemodialysis (black
bars) in patients with DM is greater (approximately threefold) than that
before hemodialysis (P< 0.01) and also greater than in non-DM patients
after hemodialysis (P< 0.01). Abbreviations: DM diabetes mellitus,
%MCVm percentage of the change in the mean middle cerebral artery
flow velocity. From Ishida et al. [9]
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could be developments in hemodialysis that have led to
expansion of the indications for hemodialysis among
older patients with multiple risk factors. In addition, use
of erythropoiesis-stimulating agents to treat anemia
might, to some extent, have increased thromboembolic
events. A possible reason for the relative decrease in
brain hemorrhage could be a decrease in heparin dose
during dialysis according to improvement in dialysis
membranes. Additionally, low-molecular weight heparin
instead of unfractionated heparin has been used for pa-
tients at high risk for hemorrhagic complications, al-
though this has not frequently been performed [3].
Effect of CKD on the severity of cerebrovascular disease
CKD is considered to affect not only the incidence of
cerebrovascular disease but also its severity. In the Fuku-
oka Stroke Registry Study, it was reported that patients
with CKD had significantly higher risks of neurological
deterioration, in-hospital mortality, and poor functional
outcome [4, 5]. These reports also demonstrated that
among the CKD components, a higher urinary protein
level was associated with an elevated risk of each outcome.
Severity of cerebrovascular disease is more prominent in
dialysis patients compared to those with non-dialysis
dependent CKD, and brain hematoma after hemorrhagic
stroke is larger and the prognosis is poorer in hemodialysis
patients [1, 2, 6].
Effect of a decrease in brain blood volume on
cerebrovascular disease during and after hemodialysis
Cerebral infarction often occurs within 6 h after the end
of hemodialysis [7]. A decrease in blood pressure has
been reported to be more pronounced in patients who
developed infarction soon after the end of dialysis than
those who developed it 6 h or longer after the end of
dialysis [1]. The mechanisms of hemodialysis-induced
cerebral infarction include a reduction in cerebral blood
flow due to increased blood viscosity and a fall in blood
pressure associated with water removal or orthopedic
hypotension following sitting up or standing up after
dialysis.
Elderly patients and those with diabetes mellitus (DM)
have severe systemic atherosclerosis and are prone to
develop dialysis-related hypotension and orthostatic
hypotension. Hemodynamic brain infarction might be
induced in these patients because of a damaged brain
autoregulation system [8]. To evaluate cerebral circula-
tion during orthostasis in patients with DM, we exam-
ined changes in mean blood flow velocity in the middle
cerebral artery during 60° of head-up tilt for 5 min in
patients with DM by using transcranial Doppler sonog-
raphy. We compared our findings with those in
hemodialysis patients without DM in the supine position[9]. We found a significant decrease in cerebral blood
flow velocity during tilt of equal magnitude in both
groups before hemodialysis, despite differences in the
level of hypotension, whereas reduction in cerebral blood
flow velocity and a decrease in mean blood pressure were
more marked in DM after hemodialysis (Fig. 1). Therefore,
orthostasis can cause hemodynamically mediated brain
damage after hemodialysis, especially in patients with
DM.
Prevention of cerebrovascular disease
Anticoagulant therapy for hemodialysis patients with atrial
fibrillation
Effect of atrial fibrillation on thromboembolic
complications Whether atrial fibrillation increases
thromboembolic complications in hemodialysis patients
is controversial. Vázquez et al. [10, 11] reported that
atrial fibrillation is relatively prevalent and its presence
increases mortality and the risk of ischemic stroke. How-
ever, Wiesholzer et al. [12] reported that atrial fibrilla-
tion itself is not associated with an increased risk of
stroke in patients on maintenance hemodialysis. Further-
more, Genovesi et al. [13] demonstrated that rates of
stroke did not significantly differ by atrial fibrillation
status, although patients with atrial fibrillation were
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fibrillation.
Advantages and disadvantages of administration of
warfarin Whether warfarin should be administered to
chronic hemodialysis patients with atrial fibrillation is
also controversial. Chan et al. [14] investigated the asso-
ciation between this medication and new stroke, mortal-
ity, and hospitalization in a retrospective cohort analysis
of 1671 incident hemodialysis patients with preexisting
atrial fibrillation. They showed that warfarin use was
associated with a significantly increased risk for new
stroke. They also demonstrated that warfarin users who
received no international normalized ratio monitoring
had the highest risk for stroke compared with nonusers.
Thereafter, similar, large-scale, observational studies
were conducted, and they concluded that warfarin use is
not beneficial in reducing the risk of stroke, but it is
associated with a higher bleeding risk in patients with
atrial fibrillation undergoing dialysis [15–17].
In contrast, only one large-scale study has recently
shown usefulness of warfarin in hemodialysis patients with
atrial fibrillation. Olesen et al. [18] conducted a study
using Danish national registries in which all 132,372 pa-
tients, including 3587 with non-dialysis-dependent CKD
and 901 with ESKD, were identified to be discharged from
the hospital with a diagnosis of non-valvular atrial fibrilla-
tion between 1997 and 2008. They estimated the risk of
stroke or systemic thromboembolism and bleeding with
the use of time-dependent Cox regression analyses and
compared the effects of treatment with warfarin, aspirin,
or both in patients with or without CKD. They showed
that the risk of stroke or systemic thromboembolism was
increased in patients with CKD and ESKD compared with
those without CKD, and such risk was decreased by treat-
ment with warfarin in both groups of patients with CKD
and ESKD.
However, there were several limitations to this study.
A larger proportion of dialysis patients had unusually
low HAS-BLED scores (HAS-BLED score 2–35 % (312/
901); 0 or 1–43 % (390/901)). Contrary to Shah’s study
and DOPPS, dialysis patients had a low prevalence of
diabetes mellitus (14 % (129/901)) and hypertension
(54 % (486/901)). It is possible that a selection bias of
healthier patients undergoing dialysis could explain the
reason for the decreased risk of stroke with warfarin use
in the study by Olesen et al.
As described above, the usefulness of warfarin has not
been established in hemodialysis patients with atrial fib-
rillation in most recently reported large-scale, observa-
tional studies (Fig. 2) [17]. In Japan, guidelines for
management of cardiovascular disease in patients on
chronic hemodialysis published by the Japanese Society
for Dialysis Therapy [1] suggest that warfarin therapyshould not be routinely performed for atrial fibrillation.
However, if considered beneficial, such therapy is desirable
to use by maintaining the prothrombin time-international
normalized ratio at <2.0. The Canadian Cardiovascular So-
ciety Atrial Fibrillation Guidelines [19] also suggest that pa-
tients with an estimated glomerular filtration rate <15 mL/
min/1.73 m2 (on dialysis) should not routinely receive
either oral anticoagulants or aspirin for prevention of
stroke in atrial fibrillation.
Novel oral anticoagulants for patients with CKD
Recently, novel oral anticoagulants (NOACs), such as
dabigatran, rivaroxaban, apixaban, and edoxaban, were
developed and clinically approved. These drugs are
superior to warfarin for prevention of ischemic stroke,
systemic embolic events, intracranial hemorrhage, and
all-cause mortality [20].
Because these drugs are excreted from the body via
the kidney, using these drugs in patients with severe
CKD is considered difficult. A systematic review of
randomized, controlled trials was conducted in patients
with CKD and defined creatinine clearance (Ccr) as 30–
50 mL/min. This review demonstrated that the use of
NOACs in select patients with CKD is effective and safe,
similar to warfarin [21].
Recently, the relationship between NOACs and acti-
vated partial thromboplastin time (aPTT) has been fo-
cused in the careful monitoring. Shimomura et al. [22]
analyzed plasma dabigatran concentration and aPTT at
various time points following administration of oral
dabigatran in 149 patients with non-valvular atrial fibril-
lation. They demonstrated that there was a significant
correlation between plasma dabigatran concentrations
and aPTT and concluded that considering the pharma-
cokinetics of dabigatran, aPTT can be used as an index
for risk screening for excess dabigatran concentrations
in Japanese patients. However, they also showed that
significantly higher dabigatran concentrations were ob-
served in samples from patients with reduced renal func-
tion (Ccr <50 mL/min) compared with those with
normal renal function (Ccr ≥50 mL/min), and the cor-
relation was lower when plasma dabigatran concentrations
were higher, suggesting the difficulties for monitoring of
dabigatran concentrations using aPTT in CKD patients.
The use of NOACs in dialysis patients is discouraged
because these drugs can bioaccumulate to precipitate in-
advertent bleeding. However, in the USA, dabigatran
and rivaroxaban use in dialysis patients with atrial fibril-
lation has steadily risen to where 5.9 % of anticoagulated
dialysis patients are started on dabigatran or rivaroxa-
ban. Chan et al. [23] reported that in covariate-adjusted
Poisson regression, dabigatran and rivaroxaban were as-
sociated with a higher risk of hospitalization or death
from bleeding compared with warfarin. Additionally, the
Fig. 2 Warfarin use and the risk for stroke in patients with atrial fibrillation undergoing dialysis. Results of evidence from previous published
studies of warfarin use and the risk for stroke in patients with atrial fibrillation undergoing dialysis are shown. Abbreviation: CI confidence
interval. From Shah et al. [17]
Fig. 3 Correlation of the changes in frontal brain atrophy and the
number of sudden blood pressure drops. The changes in frontal
atrophy index correlates significantly with the number of sudden
blood pressure drops over 3 years (r = 0.45, P < 0.05). Abbreviation:
ΔFAI the change in frontal atrophy index. From Mizumasa et al. [30]
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tran and rivaroxaban relative to warfarin, although there
were too few events in the study to detect meaningful
differences in stroke and arterial embolism between the
drug groups [23].
Prevalence of cerebral microbleeds and risk of brain
hemorrhage
Cerebral microbleeds appearing as low-signal-intensity
areas by T2*-weighted magnetic resonance imaging (MRI)
are frequently detected in patients with hypertension and
those with a history of cerebrovascular disorders. Cerebral
microbleeds are also frequently observed in CKD patients,
especially in ESKD patients [24, 25].
Cerebral microbleeds have been reported to affect the
occurrence of cerebral hemorrhage [26–29]. Naganuma
et al. [29] performed cranial MRI, including T2*-weighted
MRI, on 179 hemodialysis patients with no past history of
cerebrovascular events and followed them prospectively
until death or renal transplantation. They showed that in-
tracerebral hemorrhage occurred in only one of 134
(0.7 %) patients without cerebral microbleeds, whereas it
occurred in 11 of 45 (24.4 %) patients with cerebral micro-
bleeds during a median follow-up period of 5.0 years. This
finding suggests that hemodialysis patients with cerebral
microbleeds should be carefully monitored for future on-
set of intracerebral hemorrhage. However, whether the
risk of cerebral hemorrhage is increased by antithrombotic
therapy is unclear.
Hypotension during hemodialysis sessions
Hypotension during hemodialysis sessions might decrease
brain blood flow and induce brain infarction. In our previ-
ous study using MRI, we found a positive association
between the numbers of dialysis-related hypotension
episodes, i.e., a sudden drop in blood pressure duringHD, was arbitrarily defined as a fall in systolic blood
pressure >50 mmHg within 30 min of HD, associated
with clinical symptoms such as fatigue, clouding of con-
sciousness, muscle cramps, or other symptoms associated
with hypoperfusion of the peripheral or central nervous
system, identified from the medical records during 3 years
with progression of frontal brain atrophy (Fig. 3) [30].
Therefore, reducing the ultrafiltration rate per hour
during hemodialysis is important. Consequently, educa-
tion of patients on salt restriction is important to reduce
intradialytic weight gain. Administration of vasopressor
drugs is available and effective to prevent hypotension
during and after hemodialysis sessions. We previously
reported the effect of vasopressor drugs, such as mido-
drine hydrochloride and droxidopa, against a decrease in
brain blood flow due to orthostatic hypotension after a
hemodialysis session (Fig. 4) [31].
Fig. 4 Serial changes in %MCVm after head-up tilt test in patients treated with L-DOPS. The serial changes in %MCVm during the 5-min head-up
tilt test, before and after 4-week L-DOPS treatment at each period are shown. L-DOPS improves %MCVm decrement throughout the 5-min head-up tilt
test. Data are mean ± SEM. *P < 0.05 vs. before L-DOPS. Abbreviations: %MCVm percentage of the change in the mean middle cerebral artery flow
velocity, L-DOPS L-threo-3,4-dihydroxyphenylserine. From Fujisaki et al. [31]
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carotid artery stenosis
The prognosis after carotid endarterectomy (CEA) for
severe carotid artery stenosis in patients with CKD has
been shown to be poor [32], while better effectiveness of
CEA was reported in those patients compared with non-
CKD patients [33]. With regard to carotid artery stenting
(CAS), poorer prognosis was also reported in CKD
patients compared with non-CKD patients [34].
Using the United States Renal Data System (USRDS)
databases, Yuo et al. [35] examined the prognosis in
2131 dialysis patients (1805 CEA, 326 CAS) who under-
went CEA or CAS for asymptomatic disease from 2005
to 2008. They showed that the combined stroke or death
rate was 10.2 % at 30 days and 33.5 % at 1 year and con-
cluded that patients on dialysis have high perioperative
and long-term stroke or death rates after CEA or CAS
for asymptomatic stenosis, with a median survival of
2.5 years, which is less than that recommended by
current guidelines [36]. This finding emphasizes the im-
portance of a minimum life expectancy of at least 3 years
for there to be a benefit in asymptomatic patients under-
going CEA. According to these findings, the indications
for these procedures must be carefully evaluated.
In contrast, Okawa et al. [37] demonstrated that of 12
hemodialysis patients with carotid artery stenosis under-
going 15 CEAs, none of them showed periprocedural
complications, including stroke and myocardial infarc-
tion. They concluded that CEA may be effective for pre-
vention of stroke in hemodialysis patients.
Treatment and management of cerebrovascular disease
Management of renal failure during the acute phase of
cerebrovascular disease
Intracranial pressure autoregulation collapses immedi-
ately after the onset of brain infarction [38], and the risk
of expansion of hematoma is high within 24 h after the
onset of cerebral hemorrhage [39]. Therefore, avoidingdialysis on the day of onset is desirable. Consequently, the
need for dialysis should be carefully evaluated. If dialysis is
performed, procedures such as peritoneal dialysis, continu-
ous hemodiafiltration, and hemodialysis with restricted
blood flow, which are less likely to increase intracranial
pressure compared with usual intermittent hemodialysis,
are recommended as the dialysis techniques to be used
during the acute period. Rapid and massive removal of
water should be avoided because it exacerbates brain ische-
mia. Nafamostat mesilate is recommended to use as an
anticoagulant during hemodialysis if hemorrhagic stroke
and hemorrhagic brain infarction are concerned [1].
Thrombolytic therapy
In the last decade, thrombolytic therapy using recombin-
ant tissue plasminogen activator (rt-PA) has been ap-
plied in the clinical setting for patients with hyperacute
phase brain infarction. However, a worse prognosis with
a higher mortality and incidence of brain hemorrhage
has been reported in patients with CKD compared with
those without CKD [40, 41].
Because thrombolytic therapy has not been contraindi-
cated for hemodialysis patients, it has been applied to
hemodialysis patients in a few cases. Naganuma et al.
[42] reported the effectiveness of rt-PA therapy in four
stroke patients receiving maintenance hemodialysis with
a unique complication of ectopic cortical hematoma.
Tariq et al. [43] analyzed the data of 82,142 patients from
the Nationwide Inpatient Sample for all thrombolytic-
treated patients presenting with acute ischemic stroke in
the USA between 2002 and 2009. They showed a twofold
higher likelihood of in-hospital mortality associated with
administration of intravenous thrombolytic therapy in
1072 dialysis patients, requiring careful assessment of
the risk-benefit ratio in this population. A systematic
review recently reported by Jung et al. [44] demon-
strated that patients with CKD had a higher risk of
symptomatic intracerebral hemorrhage and mortality,
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functional status.
In spite of high risk of thrombolytic therapy for ESKD
patients on hemodialysis as described above, this therapy
is one of the important modality of treatment for pa-
tients with hyperacute phase brain infarction. Thus, if a
hemodialysis patient develops cerebrovascular disease
during or shortly after hemodialysis, the patient should
be transported to expert facilities early after the onset
[1]. Accordingly, creating a system and preparing to be
able to transport these patients as soon as possible after
the onset of are considered to be important in the
hemodialysis facilities.Endovascular mechanical thrombectomy
Recently, mechanical thrombectomy has been applied for
patients with ischemic stroke who are invalid or contrain-
dicated for thrombolytic therapy. More recently, random-
ized, controlled trials showing the usefulness of mechanical
thrombectomy for patients with acute brain infarction due
to intracranial major artery stenosis have been published
[45–49]. However, the effectiveness of mechanical thromb-
ectomy in CKD patients is unknown because all of these
trials provided no or little information on renal function
and proteinuria in the participants.
Saeed et al. [50] analyzed 2313 dialysis patients with is-
chemic stroke using data from the Nationwide Inpatient
Sample including dialysis patients presenting with acute is-
chemic stroke in the USA between 2005 and 2010. Among
these, 1398 (60 %) received intravenous thrombolytic ther-
apy and 915 (40 %) were treated with endovascular mech-
anical thrombectomy. They showed that endovascular
mechanical thrombectomy was associated with lower in-
hospital mortality and moderate-to-severe disability, even
after adjusting for age, sex, and potential confounders. Ac-
cording to these findings, the preferential use of endovas-
cular mechanical thrombectomy might be warranted in
this patient population.Conclusions
Because of the specific pathophysiology in patients with
CKD, especially those with ESKD, prevention and man-
agement of cerebrovascular disease are different from
those without CKD. However, to date, there is inad-
equate evidence on how to prevent and manage cerebro-
vascular disease in this patient population. Further
accumulation of evidence is needed to establish preven-
tion and management of cerebrovascular disease in CKD
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